Compare Kyndryl Holdings Inc (KD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Zoetis Inc — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 11.7× Kyndryl Holdings Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Zoetis Inc for 70 Days on average.
| KD | ZTS | |
|---|---|---|
Market Cap | $2.59B | $30.20B |
Volume | 5,354,348 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $28.92 | $147.53 |
52-Week Low | $10.59 | $69.09 |
Typical Hold Time | 36 Days | 70 Days |
Enterprise Value | $5.41B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% today, showing recent volatility amid mixed technical signals. The company reported positive net income of $252 million in 2025, marking a significant turnaround from prior losses, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights Kyndryl's strategic focus on AI, including the launch of an innovation lab and acquisition of Healthcare IT Leaders to drive growth.
Outlook remains cautious with analyst consensus leaning Hold (71% of ratings) and a $14.67 price target suggesting moderate upside. Key risks include declining revenue trends and competitive pressures in IT services, while opportunities lie in AI-driven modernization contracts and improved profitability. Investors should weigh the turnaround progress against execution risks in a challenging market.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
